Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT05259839 : A Dose Escalation and Expansion Study of ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaMultiple Myeloma

Trial Overview Read MoreRead more

This phase I study is assessing how safe and effective a new targeted therapy (ABBV-383) is when given in addition to other anti-cancer treatments in adults with relapsed or refractory multiple myeloma..
 

This trial is treating patients with relapsed or refractory multiple myeloma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Dose Escalation and Expansion Study of ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Commercial Sponsor

TeneoOne Inc.

Summary

Eligible participants will be allocated to one of four experimental arms. In Experimental Arm A, participants will receive ABBV-383 (via intravenous [IV] infusion) in combination with dexamethasone (via oral tablet or IV infusion) and pomalidomide (via oral capsule). In Experimental Arm B, participants will receive ABBV-383 (via IV infusion) in combination with lenalidomide (via oral capsule) and dexamethasone (via oral tablet or IV infusion). In Experimental Arm C, participants will receive ABBV-383 (via IV infusion) in combination with Daratumumab (via subcutaneous injection) and dexamethasone (via oral tablet or IV infusion). In Experimental Arm D, participants will receive ABBV-383 (via IV infusion) in combination with nirogacestat (via oral tablet).

Recruiting Hospitals Read MoreRead more

Epworth Hospital Haematology
East Melbourne
Dr Connie Barlas
connie.barlas@epworth.org.au
03 9516 2374

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next